Study of Esperoct for boys and men with hemophilia A
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study follows male participants with hemophilia A who are already taking Esperoct® as preventive (regular) treatment. It aims to learn how well this medicine works in real-world use and monitor safety over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your legal representative) must sign consent before any study steps
- Your doctor and you must have already decided to start Esperoct® before joining this study
- You must be male, and of any age
- You must have hemophilia A that is severe or moderate
- You should not have taken part in this same study before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called SCT800 for boys with severe hemophilia A who have never been treated with factor VIII before. The goal is to see if it works safely to prevent bleeding.
This study tests how well and how safely Octapharma’s clotting factor products (Nuwiq, Octanate, or Wilate) work in people with Hemophilia A who are newly treated or have had very few clotting factor doses. It also looks at how often side effects occur and how the treatments are used in real care.
This study looks at how people with hemophilia A do when they have surgery while using the medicine Altuvoct (efanesoctocog alfa). It helps doctors learn more about surgical practices for this condition.
This study tests a new medicine called Inno8 in people with haemophilia A. It looks at how different doses work in the body and may help improve treatment options.
This study collects and reviews side-effect information from the EUHASS registry in people with hemophilia. It may help doctors better understand how turoctocog alfa pegol (a clotting medicine) is tolerated in real-world care.
This study tests a new medicine called denecimig (Mim8) for adults newly diagnosed with a rare bleeding disorder called acquired hemophilia A. If you have had a bleed that needs treatment, this trial could help you manage your condition.
Hear when a new Haemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.